When will I know if shares are allotted to me?

Allotment status is usually finalized a few days after the IPO closes. Once finalized, shares are either credited to your Demat account (if allotted) or the blocked funds are released back to your bank account.

Can I modify or cancel my IPO application?

Yes, you can modify or cancel your IPO application anytime before the IPO closing date. Changes can be made through your Alice Blue account, subject to exchange cut-off timings.

What happens if the IPO is oversubscribed?

If the IPO receives more applications than the number of shares available, it is considered oversubscribed. In such cases, allotment in the retail category is done on a proportionate or lottery basis, and not all applicants may receive shares.

Gland Pharma Ltd

Complete IPO details, including price band, financials, subscription status, and key insights.

Participate in the Gland Pharma Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.

Apply for IPO

IPO Snapshot

Key metrics and details at a glance.

Price Band

₹1,500

Per Share

Lot Size

10 Shares

Minimum Investment

₹15,000

Issue Size

₹6,479.545 Cr

Face Value

₹1

Per Share

IPO Type

Book Building

Retail Quota

35%

QIB Quota

50%

NII Quota

15%

IPO Timeline

Important dates for your applying strategy.

IPO Opens9 Nov

IPO Closes11 Nov

Basis of Allotment17 Nov

Refund Initiation18 Nov

Shares Credited19 Nov

Gland Pharma Ltd

Business model, operations, and market positioning.

Issue Type

Book Building

ISIN

INE068V01023

Financial Performance

Revenue, profit after tax and total assets across the last 3 reported financial years.

Consolidated figures

Revenue GrowthProfit After Tax (PAT)Total Assets

Revenue

+13.5%vs FY24

Amount in ₹ crore

Objects of the Issue

How the company plans to utilize IPO proceeds.

Use of Proceeds

The funds raised through this IPO will be used for:

Initial public offer of 43196968 equity shares of face value of Re. 1 each ("equity shares") of Gland Pharma Limited ("Company" or "Issuer") for cash at a price of Rs.1500 Per equity share (including a share premium of Rs.1499 per equity share) aggregating Rs.6479.55 crores (The "Offer") comprising a fresh issue of 8,333,333 equity shares aggregating up to Rs. 1250 crores on (The "fresh issue") and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd ("promoter selling shareholder") and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the "other selling shareholders" and collectively With the promoter selling shareholder are referred to as the "selling shareholders", and such equity shares, the "offered shares") aggregating up to Rs. 5229.55 crores (the "offer for sale"). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is Rs.1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is Rs.1500 per Equity Share.

*Subject to approvals and market conditions.

Strengths & Risks

Key competitive advantages and factors to consider before investing.

StrengthsRisk Factors

Company's industry is heavily regulated and its business activities require various approvals, licenses, registrations and permissions. If there is any change to such regulations or failure or delay in obtaining necessary permits or approvals, or if such permits or approvals are revoked or not renewed for any reason, its business, financial condition, cash flows and results of operations may be adversely affected.
Company is dependent on its business arrangements with its marketing partners and customers for the sale of its products. If any of these arrangements is terminated for any reason, or if its marketing partners fail to fulfil their obligations under the relevant agreements or otherwise do not effectively sell or market its products, or if its relationships with any of its marketing partners and customers are disrupted, its business, financial condition, cash flows and results of operations may be adversely affected.

Frequently Asked Questions

What is the minimum investment required to apply for this IPO?

The minimum investment depends on the lot size and the upper price band of the issue. Investors must apply for at least one lot, and the total investment amount is calculated by multiplying the lot size by the upper price band.

How is IPO allotment decided?

IPO allotment is determined based on demand and SEBI guidelines. If the IPO is oversubscribed in the retail category, allotment is typically done through a computerized lottery system to ensure fair distribution among eligible applicants.

Objects of the Issue

How the company plans to utilize IPO proceeds.

Use of Proceeds

The funds raised through this IPO will be used for:

*Subject to approvals and market conditions.

Strengths & Risks

Key competitive advantages and factors to consider before investing.

StrengthsRisk Factors

Company's industry is heavily regulated and its business activities require various approvals, licenses, registrations and permissions. If there is any change to such regulations or failure or delay in obtaining necessary permits or approvals, or if such permits or approvals are revoked or not renewed for any reason, its business, financial condition, cash flows and results of operations may be adversely affected.
Company is dependent on its business arrangements with its marketing partners and customers for the sale of its products. If any of these arrangements is terminated for any reason, or if its marketing partners fail to fulfil their obligations under the relevant agreements or otherwise do not effectively sell or market its products, or if its relationships with any of its marketing partners and customers are disrupted, its business, financial condition, cash flows and results of operations may be adversely affected.

Gland Pharma Ltd

IPO Snapshot

IPO Timeline

Gland Pharma Ltd